Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Jan. 31, 2018
Jan. 31, 2017
Revenue
Operating costs and expenses:    
Inventor royalties, contingent legal fees and litigation and licensing expenses related to patent assertion 25,353 2,121
Amortization of patents 81,324 81,324
Research and development expenses (including non-cash stock option compensation expense of $40,057 and $79,700, respectively) 777,873 451,630
General and administrative expenses (including non-cash stock option compensation expense of $226,916 and $180,037 respectively) 990,036 859,885
Total operating costs and expenses 1,874,586 1,394,960
Loss from operations (1,874,586) (1,394,960)
Interest expense (195,299)
Interest income 9,112 999
Loss before income taxes (1,865,474) (1,589,260)
Provision for income taxes
Net loss (1,865,474) (1,589,260)
Less: Net loss attributable to noncontrolling interest (27,402)
Net loss attributable to common shareholders before deemed dividend (1,838,072) (1,589,260)
Deemed dividend to preferred shareholder (Note 6) (2,008,775)
Net loss attributable to common shareholders $ (1,838,072) $ (3,598,035)
Net loss per share attributable to common shareholders:    
Basic and diluted (in Dollars per share) $ (0.11) $ (0.41)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 16,610,770 8,755,057